Literature DB >> 19094820

Pharmacokinetics of antibiotics or antifungal drugs in intensive care units.

Guillaume Dufour1, Philippe Montravers.   

Abstract

Intensive care unit (ICU) patients present several unusual pharmacokinetic (PK) characteristics compared with less seriously ill patients, including increased distribution volume and variable clearance. Interpatient PK variability is often considerable and can produce a wide range of values for PK parameters and major differences in drug exposure. These analyses have led to the development of simulation techniques and population PK models to assess dosing regimens in specific patient subsets. Plasma concentrations may frequently overestimate target-site concentrations and therefore clinical efficacy. The unbound drug concentration at the infection site should be preferred. Although renal replacement therapy techniques are commonly used in ICU patients, data concerning antibiotic dosing in this setting remain limited. Administration of antibacterial agents by continuous infusion is becoming a common technique to avoid undesirable high peak concentrations and low trough concentrations and to optimize PK-pharmacodynamic indices.

Entities:  

Year:  2009        PMID: 19094820     DOI: 10.1007/s11908-009-0003-9

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  49 in total

1.  Levels of vancomycin in the cerebral interstitial fluid after severe head injury.

Authors:  Anselmo Caricato; Mariano Pennisi; Aldo Mancino; Gianluca Vigna; Claudio Sandroni; Andrea Arcangeli; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

2.  Clearance of linezolid via continuous venovenous hemodiafiltration.

Authors:  Laurie S Mauro; Charles A Peloquin; Kimberly Schmude; Ragheb Assaly; Deepak Malhotra
Journal:  Am J Kidney Dis       Date:  2006-06       Impact factor: 8.860

3.  Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure.

Authors:  Enrico Fiaccadori; Umberto Maggiore; Carlo Rotelli; Roberto Giacosa; Elisabetta Parenti; Edoardo Picetti; Sibilla Sagripanti; Paola Manini; Roberta Andreoli; Aderville Cabassi
Journal:  Crit Care Med       Date:  2004-12       Impact factor: 7.598

4.  Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.

Authors:  Emmanuel Boselli; Dominique Breilh; Thomas Rimmelé; Sarah Djabarouti; Jérôme Toutain; Dominique Chassard; Marie-Claude Saux; Bernard Allaouchiche
Journal:  Crit Care Med       Date:  2005-07       Impact factor: 7.598

5.  Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.

Authors:  Olaf Burkhardt; Vipul Kumar; Denise Katterwe; Jolanta Majcher-Peszynska; Bernd Drewelow; Hartmut Derendorf; Tobias Welte
Journal:  J Antimicrob Chemother       Date:  2006-12-21       Impact factor: 5.790

6.  Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia.

Authors:  Emmanuel Boselli; Dominique Breilh; Marie-Claude Saux; Jean-Baptiste Gordien; Bernard Allaouchiche
Journal:  Intensive Care Med       Date:  2006-10-13       Impact factor: 17.440

7.  Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.

Authors:  Andrea Novelli; Chiara Adembri; Paola Livi; Stefania Fallani; Teresita Mazzei; Angelo Raffaele De Gaudio
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration.

Authors:  Valentin Fuhrmann; Peter Schenk; Walter Jaeger; Michaela Miksits; Nikolaus Kneidinger; Joanna Warszawska; Ulrike Holzinger; Reinhard Kitzberger; Florian Thalhammer
Journal:  J Antimicrob Chemother       Date:  2007-09-13       Impact factor: 5.790

9.  The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient.

Authors:  Hervé Quintard; Emmanuelle Papy; Laurent Massias; Sigismond Lasocki; Philippe Arnaud; Jean-Marie Desmonts; Philippe Montravers
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

10.  Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.

Authors:  Arantxazu Isla; Alicia Rodríguez-Gascón; Iñaki F Trocóniz; Lorea Bueno; María Angeles Solinís; Javier Maynar; José Angel Sánchez-Izquierdo; José Luis Pedraz
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more
  4 in total

1.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Local delivery polymer provides sustained antifungal activity of amphotericin B with reduced cytotoxicity.

Authors:  Rebecca M Haley; Sean T Zuckerman; Catherine A Gormley; Julius N Korley; Horst A von Recum
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-21

3.  Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.

Authors:  Bernard Georges; Jean-Marie Conil; Thierry Seguin; Stéphanie Ruiz; Vincent Minville; Pierre Cougot; Jean-François Decun; Hélène Gonzalez; Georges Houin; Olivier Fourcade; Sylvie Saivin
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

4.  The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysis.

Authors:  Andrzej Wieczorek; Andrzej Tokarz; Wojciech Gaszynski; Tomasz Gaszynski
Journal:  Drug Des Devel Ther       Date:  2014-10-23       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.